Human Organ-on-a-Chip Technologies Offer Promise, Face Hurdles to Widespread Adoption

Laboratory devices that mimic human organs, known as human organ-on-a-chip (OOC) technologies, are gaining attention for their potential to complement and, in some cases, improve upon conventional methods such as animal testing in biomedical research. These chips, engineered using human cells to replicate functions of organs like the brain, heart, and lungs, are being used to model diseases and assess drug safety. However, significant challenges are slowing their broader integration into research and regulatory processes.

According to a new report from the U.S. Government Accountability Office, the development and implementation of OOCs is hindered by the limited availability of high-quality human cells. Experts reported that only a fraction of purchased cells meet the necessary standards for OOC studies. Additionally, the field lacks standardized benchmarks and sufficient validation studies, making it difficult for researchers and pharmaceutical companies to fully assess the accuracy and reliability of these systems compared to traditional testing methods.

Compounding the issue is the limited data sharing between competing developers, which is often driven by concerns over intellectual property and competitive positioning. This reluctance stifles collaboration and slows the generation of evidence that could support wider adoption. Regulatory uncertainty is another barrier, with federal agencies such as the FDA still determining how OOCs can fit within existing frameworks. Experts have noted a general lack of familiarity and clear guidance from regulators regarding how OOCs can be used to meet regulatory requirements.

To address these challenges, the GAO has proposed six policy options. These include increasing access to high-quality and diverse human cells, encouraging the development of validation studies, promoting precompetitive data-sharing mechanisms, and issuing more specific regulatory guidance. For example, the establishment of centralized cell banks and biospecimen repositories could improve cell quality and availability. Similarly, dedicated funding for benchmark research could boost confidence in OOC results, and clearer regulatory direction could help integrate the technology into drug development pipelines.

While OOCs are not yet positioned to replace animal testing entirely, they represent a critical step toward more human-relevant research models. Next-generation developments are exploring interconnected “body-on-a-chip” systems that simulate interactions between multiple organs, potentially offering more comprehensive insights into human physiology and disease.

Article by multiple RFHC contributors, based upon information from the U.S. Government Accountability Office (GAO-25-107335)

---